People with cardiovascular disease (i.e. affecting the heart and blood vessels) who use low-dose colchicine for at least six months will reduce their risk of myocardial infarction (heart attack) and ...

Preterm infants requiring special and intensive care usually have problems with breathing, leading to organ damage, including brain damage. Caffeine helps preterm infants to breathe and decreases the ...

In people with cancer, CBT-I may slightly improve insomnia severity, sleep quality, and most sleep diary parameters without introducing additional unwanted or harmful events. However, we are very ...

We offer our services and tools to the wider evidence community through licences and custom projects. All income is used to support our charitable aims and mission. Streamline systematic reviews and ...

The Cochrane Collaboration is a charity (no. 1045921) and a company limited by guarantee (no. 03044323) registered in England & Wales. VAT registration number GB 718 2127 49.

75 % der Leitlinien der Weltgesundheitsorganisation, die in den letzten 5 Jahren neu erstellt wurden, zitieren mindestens ...

Compared to placebo (a sham medication), tirzepatide likely helps adults with obesity lose weight in the medium term (up to 2 years), and this weight reduction is likely to be maintained over the long ...

75 % des nouvelles revues de l'Organisation mondiale de la Santé des cinq dernières années citent au moins une revue Cochrane ...

El 75 % de las nuevas guías de la Organización Mundial de la Salud de los últimos 5 años citan al menos una revisión Cochrane ...

Adults with obesity lose more weight with semaglutide than with placebo (a sham medication). However, the risk of unwanted events is probably higher than with placebo after 24 months. Semaglutide ...

75% novih smjernica Svjetske zdravstvene organizacije u posljednjih 5 godina citira barem jedan Cochraneov sustavni pregled.

75% новых руководств Всемирной организации здравоохранения за последние 5 лет ссылаются как минимум на один Кокрейновский ...